Aurinia Pharmaceuticals Inc.
AUPH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AUPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AUPH
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, with its flagship product LUPKYNIS (voclosporin) approved for the treatment of adult patients with active lupus nephritis.
Key risk: Single product dependency
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 8 clinical trials · 1 catalyst · 1 FDA decision for Aurinia Pharmaceuticals Inc..
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, with its flagship product LUPKYNIS (voclosporin) approved for the treatment of adult patients with active lupus nephritis.
- LUPKYNIS is the first FDA-approved oral therapy for adult patients with active lupus nephritis and grew 36% to $216.2 million in revenue in 2024 [sec · filed 2025-04-17].
- As of June 30, 2026, Aurinia reported cash & equivalents of $179.8M, total revenue of $83.2M, net income of $37.4M, shareholders' equity of $335.3M, and total debt of $43.9M [sec].
- The company is developing AUR200, a next-generation therapy targeting both BAFF and APRIL for autoimmune diseases, with Phase 1 SAD study data anticipated in the first half of 2025 [sec_mda · as of 2024-08-01].
- Aurinia repurchased 6.1 million common shares under its share repurchase plan in 2024 [sec · filed 2025-04-17].
- The company has a global partnership with Otsuka for LUPKYNIS commercialization [sec · filed 2024-05-03].
What works
- LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis, a significant unmet medical need, and has shown strong revenue growth of 36% in 2024 [sec · filed 2025-04-17].
- The company has a robust financial position with $179.8M in cash and equivalents as of June 30, 2026, and generated positive net income of $37.4M in the same period [sec].
- Aurinia's pipeline includes AUR200, a potentially differentiated therapy targeting both BAFF and APRIL, with clinical data expected in the first half of 2025 [sec_mda · as of 2024-08-01].
What to weigh
- Aurinia's revenue is heavily dependent on a single product, LUPKYNIS, making it vulnerable to market competition or regulatory changes [sec · filed 2025-04-17].
- The company has a history of net losses and accumulated deficit, though recent quarters show profitability; as of June 30, 2026, net income was $37.4M [sec].
- The patent for LUPKYNIS is set to expire on December 7, 2037, which could expose the product to generic competition [upcoming catalysts].
From the filings
Quoted directly from source documents.
LUPKYNIS revenue growth and market position
“YNIS ® , our flagship product and the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, grew 36% to $216.2 million in 2024, its fourth year on the market.”
SEC filings · April 17, 2025
Financial position as of December 31, 2024
“As of December 31, 2024, Aurinia had cash, cash equivalents, restricted cash and short-term investments of $358.5 million and zero debt.”
SEC filings · April 17, 2025
AUR200 pipeline development
“The Company is moving forward with development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).”
SEC MD&A · August 1, 2024
Partnership with Otsuka
“we have continued to focus on increasing our revenue from sales of LUPKYNIS, and building our global partnership with Otsuka.”
SEC filings · May 3, 2024
Catalyst timeline
- 2037-12-07 · Patent_Expiry · LUPKYNIS — Patent/Exclusivity Expiry: LUPKYNIS — The patent for LUPKYNIS expires, which could allow generic competition and impact revenue.
Risks & what to watch (3)›
Key risks
- Single product dependency — Aurinia's revenue is almost entirely dependent on LUPKYNIS, making it vulnerable to competition or regulatory changes [sec · filed 2025-04-17].
- Patent expiration — LUPKYNIS patent expires on December 7, 2037, potentially allowing generic competition [upcoming catalysts].
- Clinical development risk — Pipeline candidate AUR200 is in early-stage trials; failure could delay pipeline growth [sec_mda · as of 2024-08-01].
What to watch
- Phase 1 SAD study data for AUR200 anticipated in the first half of 2025 [sec_mda · as of 2024-08-01].
- LUPKYNIS revenue growth trajectory and market share in lupus nephritis [sec · filed 2025-04-17].
- Patent expiration for LUPKYNIS on December 7, 2037, and potential generic entry [upcoming catalysts].
- Cash burn rate and ability to maintain profitability given $179.8M cash as of June 30, 2026 [sec].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Aurinia Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aurinia Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.29 · 3% dilution
No tracked pipeline phase
1 candidate
1 upcoming, next in ~4117d
6 buys · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
258
Total value held
$1.04B
| Holder | Shares | Value |
|---|---|---|
| tang capital management llc | 12,229,500 | $181.2M |
| blackrock, inc. | 7,845,521 | $116.3M |
| two sigma investments, lp | 3,428,705 | $50.8M |
| arrowstreet capital, limited partnership | 3,284,368 | $48.7M |
| state street corp | 2,527,099 | $37.5M |
| morgan stanley | 2,232,548 | $33.1M |
| marshall wace, llp | 1,874,597 | $27.8M |
| renaissance technologies llc | 1,663,835 | $24.7M |
| d. e. shaw & co., inc. | 1,572,983 | $23.3M |
| geode capital management, llc | 1,536,009 | $22.8M |
Showing top 10 of 258 institutional holders of Aurinia Pharmaceuticals Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 7.6%
- Days to cover
- 8.1
- Shares short
- 8,886,775
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AUPH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aurinia Pharmaceuticals Inc.?
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, with its flagship product LUPKYNIS (voclosporin) approved for the treatment of adult patients with active lupus nephritis.
What is Aurinia Pharmaceuticals Inc.'s lead drug candidate?
Aurinia Pharmaceuticals Inc.'s most advanced tracked candidate is LUPKYNIS (Phase 4) for Lupus Nephritis.
What is Aurinia Pharmaceuticals Inc.'s next catalyst?
Aurinia Pharmaceuticals Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: LUPKYNIS" — expected December 7, 2037.
Who is the CEO of Aurinia Pharmaceuticals Inc.?
Mr. Kevin C. Tang is the chief executive officer of Aurinia Pharmaceuticals Inc. (AUPH).
Where is Aurinia Pharmaceuticals Inc. headquartered?
Aurinia Pharmaceuticals Inc. (AUPH) is headquartered in Edmonton, AB, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.